Long-Term Evolution of Cytophagic Histiocytic Panniculitis

Abstract

Nevertheless, the long-term evolution of this entity has not been described yet, nor have precise recommendations regarding the most adequate posology and duration of therapy. We report the result of switching from a long-term cyclosporine therapy to tacrolimus in a patient with a severe form of cytophagic histiocytic panniculitis.

Successful treatment of cyclosporine-A-resistant cytophagic histiocytic panniculitis with tacrolimus

“…Recently, Fernández [13] reported the first CHP case treated with TAC and mentioned that TAC might be considered an alternative therapy for patients with CHP who have toxicity or intolerance to CsA. However, taking our case and Fernández's case into consideration, TAC may not only be a salvage therapy for CsA-resistant CHP but also have a potential as a first-line treatment modality.…”